Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GoHealth Reports Second Quarter 2021 Results

      Revises Full Year 2021 Growth Outlook

      GoHealth, Inc. (PRNewsfoto/GoHealth, Inc.)

      News provided by

      GoHealth, Inc.

      Aug 11, 2021, 16:05 ET

      Share this article

      Share this article


      CHICAGO, Aug. 11, 2021 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and six months ended June 30, 2021.

      • Second quarter 2021 net revenue of $196.9 million increased 55% compared to the prior year period. YTD 2021 net revenue of $401.1 million increased 50% compared to the prior year period.
      • Second quarter 2021 Medicare—Internal revenue of $160.4 million increased 84% compared to the prior year period. YTD 2021 Medicare—Internal revenue of $317.8 million increased 74% compared to the prior year period.
      • Second quarter 2021 Medicare Advantage ("MA") Approved Submissions of 152,749 increased 58% compared to the prior year period. YTD 2021 MA Approved Submissions of 323,876 increased 52% compared to the prior year period.
      • Second quarter 2021 MA LTV Per Approved Submission of $953 increased 5% compared to the prior year period. YTD 2021 MA LTV Per Approved Submission of $975 increased 11% compared to the prior year period.
      • Second quarter 2021 net loss of $39.2 million compared to a net loss of $22.9 million in the prior year period; Adjusted EBITDA1 of $14.3 million decreased 47% compared to the prior year period due to the 2021 strategic investments in agent capacity, marketplace technology, branding and the Encompass Platform. YTD 2021 net loss was $46.4 million compared to a net loss of $23.8 million in the prior year period; Adjusted EBITDA1 of $46.4 million decreased 25% compared to the prior year period.
      • The Company tightened its full year 2021 revenue outlook to $1,200 - $1,300 million (+37% to +48%) powered by commission net revenue of $1,000 - $1,100 million (+49% to +64%) as agent growth is tracking at the high end of expectations. The Company lowered its Adjusted EBITDA1 outlook to $300 - $330 million (+11% to +22%), primarily due to higher agent costs expected in 2021.

      Clint Jones, co-founder and CEO said, "GoHealth's second quarter revenue growth of 55% was driven by an 84% gain in our Medicare—Internal segment with LTVs expanding 5%. Our ramped up investments in our Encompass Platform led to $17 million in revenue contribution from the platform's additional services beyond enrollment for carriers. Given the 50% top-line growth over the first six months and continued strength in the market, we have raised and tightened our revenue expectations for full year fiscal 2021."

      Jones continued, "These excellent top-line results are enabled by our success at increasing our agent counts ahead of the 50% growth target, ensuring that we have ample agent capacity to address the anticipated demand during this year's Annual Enrollment Period. While we are encouraged by the growth in our agent force, enhanced training and tight labor markets have created cost pressures that we expect to continue over the balance of the year. Given these higher agent costs, we are reducing our outlook for 2021 Adjusted EBITDA. We anticipate that these 2021 investments in agents, training, technology and Encompass will position us well for continued strong efficient growth in 2022."

      Second Quarter 2021 Highlights2

      • Total company revenue grew 55% to $196.9 million
        • Total Medicare Commissionable Submitted Policies grew 52% to 156,559
      • Medicare—Internal net revenue increased 84% to $160.4 million
      • LTV Per carrier Approved MA Submission increased 5% to $953
      • Adjusted EBITDA1 decreased 47% to $14.3 million
        • Aggregate investment in customer care and enrollment and technology grew $39.8 million to $73.9 million, an increase of 117%, including enhanced tools and training to continue powering conversion gains and improved effectuation, as well as investments in the Encompass platform
          • Agent counts grew well ahead of the 50% target as the Company prepares for the Annual Enrollment Period and fiscal 2022
        • Total cost of revenue, marketing and advertising expense grew 60%, roughly in line with sales growth
      • The Company refinanced a portion of its term loans, upsized its revolver to $200 million, and lowered its annual borrowing costs by over $7 million

      YTD 2021 Highlights2

      • Total company revenue grew 50% to $401.1 million
        • Total Medicare Commissionable Submitted Policies grew 48% to 333,130
      • Medicare—Internal net revenue increased 74% to $317.8 million
        • Medicare—Internal segment profit increased 4% to $77.7 million
      • LTV Per carrier Approved MA Submission increased 11% to $975
      • Adjusted EBITDA1 decreased 25% to $46.4 million
        • Aggregate investment in customer care and enrollment and technology grew 108% to $68.0 million
        • Total cost of revenue, marketing and advertising expense grew 55%, roughly in line with sales growth

      2021 Financial Outlook

      The trajectory of the U.S. economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. The Company is revising its financial outlook for the fiscal year ending December 31, 2021 based on current market conditions and expectations:

      • Full-year 2021 net revenue of $1,200 - $1,300 million, representing year-over-year growth of 37% - 48%
        • Full-year 2021 commission revenue of $1,000 - $1,100 million, representing year-over-year growth of 49% - 64%, fueled by the Company's continued investment in its Medicare business, including GoHealth's Encompass Platform
      • Full-year 2021 Adjusted EBITDA1 of $300 - $330 million, representing year-over-year growth of 11% - 22%

      Jones added, "Seniors continue to demonstrate a high degree of interest in our model, and increasingly want to explore their Medicare plan choices from the safety and comfort of their own home through our Choice platform. GoHealth's telesales agents are equipped with the decision support tools and experience to help consumers select the right plan for their unique needs and achieve a superior health outcome with lower costs. We are in the early days of realizing this enormous market opportunity by building GoHealth's position as the trusted advisor for consumers, helping these consumers navigate their healthcare journey through our Encompass offerings, and in the process, creating value for our carrier partners through driving high-quality enrollments."

      Conference Call Details

      The Company will host a conference call today, Wednesday, August 11, 2021 at 5:00 p.m. (ET) to discuss its financial results.  A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 5464567. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

      About GoHealth, Inc.:

      As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. Since its inception, GoHealth has enrolled millions of people in Medicare and individual and family plans. For more information, visit https://www.gohealth.com.

      Investor Relations:
      Jay Koval, VP of Investor Relations
      [email protected]  

      Media Relations:
      [email protected]


      (1)

      Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

      (2)

      Second quarter and YTD 2021 results compared to the comparable prior year period.

      Forward-Looking Statements

      This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected financial performance and operational performance for the fiscal year 2021, including with respect to revenue and Adjusted EBITDA are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but are not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationship; failure to grow the Company's customer base or retain its existing customers; the time and cost of training agents are significant and can increase during a period of high attrition; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; significant consolidation in the healthcare industry which could adversely alter the Company's relationships with carriers; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; changes in the health insurance system and laws and regulation governing health insurance markets; the inability to effectively advertise the Company's products; and our ability to successfully implement our business plan during a global economic downturn caused by the COVID-19 pandemic.

      The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      Use of Non-GAAP Financial Measures and Key Performance Indicators

      In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense ("EBITDA"); Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

      Adjusted EBITDA represents EBITDA as further adjusted for share-based compensation, loss on debt extinguishment, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

      We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

      The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

      Management has provided its outlook regarding Adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Reconciliations of Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), is presented in the table below in this press release.

      Glossary

      "Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, loss on extinguishment of debt, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs.

      "Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

      "Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

      "LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

      "Revenue Per Submission" refers to the total net revenues per Submitted Policy, which we define as (i) total net revenue, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of Submitted Policies for such period.

      "Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

      The following tables set forth the components of our results of operations for the periods indicated (unaudited):

      (in thousands, except percentages and per share amounts)


      Three months ended Jun.
      30, 2021


      Three months ended Jun.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $

      147,508



      74.9

      %


      $

      96,606



      76.0

      %


      $

      50,902



      52.7

      %

      Enterprise


      49,394



      25.1

      %


      30,451



      24.0

      %


      18,943



      62.2

      %

      Net revenues


      196,902



      100.0

      %


      127,057



      100.0

      %


      69,845



      55.0

      %

      Operating expenses:













      Cost of revenue


      37,442



      19.0

      %


      36,559



      28.8

      %


      883



      2.4

      %

      Marketing and advertising


      55,735



      28.3

      %


      21,634



      17.0

      %


      34,101



      157.6

      %

      Customer care and enrollment


      61,927



      31.5

      %


      28,394



      22.3

      %


      33,533



      118.1

      %

      Technology


      11,983



      6.1

      %


      5,705



      4.5

      %


      6,278



      110.0

      %

      General and administrative


      25,251



      12.8

      %


      10,359



      8.2

      %


      14,892



      143.8

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      15,300



      12.0

      %


      (15,300)



      N/M

      Amortization of intangible assets


      23,515



      11.9

      %


      23,514



      18.5

      %


      1



      —

      %

      Total operating expenses


      215,853



      109.6

      %


      141,465



      111.3

      %


      74,388



      52.6

      %

      Income (loss) from operations


      (18,951)



      (9.6)

      %


      (14,408)



      (11.3)

      %


      (4,543)



      31.5

      %

      Interest expense


      8,277



      4.2

      %


      8,986



      7.1

      %


      (709)



      (7.9)

      %

      Loss on extinguishment of debt


      11,935



      6.1

      %


      —



      —

      %


      11,935



      N/M

      Other (income) expense


      44



      —

      %


      (505)



      (0.4)

      %


      549



      N/M

      Income (loss) before income taxes


      (39,207)



      (19.9)

      %


      (22,889)



      (18.0)

      %


      (16,318)



      71.3

      %

      Income tax expense (benefit)


      (32)



      —

      %


      (22)



      —

      %


      (10)



      N/M

      Net income (loss)


      $

      (39,175)



      (19.9)

      %


      $

      (22,867)



      (18.0)

      %


      $

      (16,308)



      71.3

      %

      Net income (loss) attributable to noncontrolling interests


      (27,186)



      (13.8)

      %









      Net income (loss) attributable to GoHealth, Inc.


      $

      (11,989)



      (6.1)

      %









      Net income (loss) per share:













      Net income (loss) per share of common stock — basic and diluted


      $

      (0.12)












      Weighted-average shares of common stock outstanding — basic and diluted


      102,300












      Non-GAAP financial measures:













      EBITDA


      $

      (5,192)





      $

      10,615








      Adjusted EBITDA


      $

      14,342





      $

      26,936








      Adjusted EBITDA margin


      7.3

      %




      21.2

      %







      _________________________

      NM = Not meaningful

      (in thousands, except percentages and per share amounts)


      Six months ended Jun.
      30, 2021


      Six months ended Jun.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $

      321,489



      80.2

      %


      $

      209,116



      78.0

      %


      $

      112,373



      53.7

      %

      Enterprise


      79,592



      19.8

      %


      58,951



      22.0

      %


      20,641



      35.0

      %

      Net revenues


      401,081



      100.0

      %


      268,067



      100.0

      %


      133,014



      49.6

      %

      Operating expenses:













      Cost of revenue


      85,817



      21.4

      %


      78,693



      29.4

      %


      7,124



      9.1

      %

      Marketing and advertising


      110,219



      27.5

      %


      47,708



      17.8

      %


      62,511



      131.0

      %

      Customer care and enrollment


      109,021



      27.2

      %


      52,371



      19.5

      %


      56,650



      108.2

      %

      Technology


      21,600



      5.4

      %


      10,298



      3.8

      %


      11,302



      109.7

      %

      General and administrative


      44,944



      11.2

      %


      20,849



      7.8

      %


      24,095



      115.6

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      19,700



      7.3

      %


      (19,700)



      N/M

      Amortization of intangible assets


      47,029



      11.7

      %


      47,029



      17.5

      %


      —



      —

      %

      Total operating expenses


      418,630



      104.4

      %


      276,648



      103.2

      %


      141,982



      51.3

      %

      Income (loss) from operations


      (17,549)



      (4.4)

      %


      (8,581)



      (3.2)

      %


      (8,968)



      104.5

      %

      Interest expense


      16,965



      4.2

      %


      15,742



      5.9

      %


      1,223



      7.8

      %

      Loss on extinguishment of debt


      11,935



      3.0

      %


      —



      —

      %


      11,935



      N/M

      Other (income) expense


      57



      —

      %


      (495)



      (0.2)

      %


      552



      (111.5)

      %

      Income (loss) before income taxes


      (46,506)



      (11.6)

      %


      (23,828)



      (8.9)

      %


      (22,678)



      95.2

      %

      Income tax expense (benefit)


      (63)



      —

      %


      (24)



      —

      %


      (39)



      N/M

      Net income (loss)


      $

      (46,443)



      (11.6)

      %


      $

      (23,804)



      (8.9)

      %


      $

      (22,639)



      95.1

      %

      Net loss attributable to noncontrolling interests


      (32,364)



      (8.1)

      %









      Net loss attributable to GoHealth, Inc.


      $

      (14,079)



      (3.5)

      %









      Net income (loss) per share:













      Net income (loss) per share of common stock — basic and diluted


      $

      (0.14)












      Weighted-average shares of common stock outstanding — basic and diluted


      97,349












      Non-GAAP financial measures:













      EBITDA


      $

      21,564





      $

      40,579








      Adjusted EBITDA


      $

      46,390





      $

      61,857








      Adjusted EBITDA margin


      11.6

      %




      23.1

      %







      _________________________

      NM = Not meaningful


      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

      (in thousands)


      Three months ended Jun. 30, 2021


      Three months ended Jun. 30, 2020

      Net revenues


      $

      196,902



      $

      127,057


      Net income (loss)


      (39,175)



      (22,867)


      Interest expense


      8,277



      8,986


      Income tax expense (benefit)


      (32)



      (22)


      Depreciation and amortization expense


      25,738



      24,518


      EBITDA


      (5,192)



      10,615


      Loss on extinguishment of debt (1)


      11,935



      —


      Share-based compensation expense (2)


      7,599



      597


      Change in fair value of contingent consideration liability (3)


      —



      15,300


      IPO transaction costs (4)


      —



      424


      Adjusted EBITDA


      $

      14,342



      $

      26,936


      Adjusted EBITDA margin


      7.3

      %


      21.2

      %

      _________________________

      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (3)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (4)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (in thousands)


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Net revenues


      $

      401,081



      $

      268,067


      Net income (loss)


      (46,443)



      (23,804)


      Interest expense


      16,965



      15,742


      Income tax expense (benefit)


      (63)



      (24)


      Depreciation and amortization expense


      51,105



      48,665


      EBITDA


      21,564



      40,579


      Loss on extinguishment of debt (1)


      11,935



      —


      Share-based compensation expense (2)


      12,711



      1,077


      Legal fees (3)


      180



      —


      Change in fair value of contingent consideration liability (4)


      —



      19,700


      IPO transaction costs (5)


      —



      424


      Severance costs (6)


      —



      77


      Adjusted EBITDA


      $

      46,390



      $

      61,857


      Adjusted EBITDA margin


      11.6

      %


      23.1

      %

      _________________________

      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (3)

      Represents non-recurring legal fees unrelated to our core operations.

      (4)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (5)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (6)

      Represents costs associated with the termination of employment.


      The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

      (in thousands)


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun.
      30, 2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Marketing and advertising


      $

      426



      $

      61



      $

      764



      $

      119


      Customer care and enrollment


      1,043



      32



      1,839



      58


      Technology


      1,133



      83



      1,880



      159


      General and administrative


      4,997



      421



      8,228



      741


      Total share-based compensation expense


      $

      7,599



      $

      597



      $

      12,711



      $

      1,077


      The following table sets forth our balance sheets for the periods indicated (unaudited):

      (in thousands, except per share amounts)


      Jun. 30, 2021


      Dec. 31, 2020

      Assets





      Current assets:





      Cash and cash equivalents


      $

      112,863



      $

      144,234


      Accounts receivable, net of allowance for doubtful accounts of $686 in 2021 and $787 in 2020


      17,335



      14,211


      Receivable from NVX Holdings, Inc.


      —



      3,395


      Commissions receivable - current


      113,062



      188,128


      Prepaid expense and other current assets


      52,992



      41,854


      Total current assets


      296,252



      391,822


      Commissions receivable - non-current


      761,011



      622,270


      Other long-term assets


      2,594



      2,072


      Property, equipment, and capitalized software, net


      23,527



      17,353


      Intangible assets, net


      641,697



      688,726


      Goodwill


      386,553



      386,553


      Total assets


      $

      2,111,634



      $

      2,108,796


      Liabilities and Stockholders' Equity





      Current liabilities:





      Accounts payable


      $

      17,080



      $

      8,733


      Accrued liabilities


      31,036



      26,926


      Commissions payable - current


      51,579



      78,478


      Deferred revenue


      700



      736


      Current portion of long-term debt


      4,270



      4,170


      Other current liabilities


      9,207



      8,328


      Total current liabilities


      113,872



      127,371


      Non-current liabilities:





      Commissions payable - non-current


      214,237



      182,596


      Long-term debt, net of current portion


      414,908



      396,400


      Other non-current liabilities


      2,817



      3,274


      Total non-current liabilities


      631,962



      582,270


      Stockholders' equity:





      Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 105,318 and 84,196 shares issued and
      outstanding at June 30, 2021 and December 31, 2020, respectively.


      10



      8


      Class B common stock – $0.0001 par value; 597,502 and 619,004 shares authorized; 215,495 and 236,997 shares
      issued and outstanding at June 30, 2021 and December 31, 2020, respectively.


      22



      24


      Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at June 30, 2021 and
      December 31, 2020.


      —



      —


      Additional paid-in capital


      503,689



      399,169


      Accumulated other comprehensive income (loss)


      (13)



      17


      Accumulated deficit


      (32,881)



      (18,802)


      Total stockholders' equity attributable to GoHealth, Inc.


      470,827



      380,416


      Non-controlling interests


      894,973



      1,018,739


      Total stockholders' equity


      1,365,800



      1,399,155


      Total liabilities and stockholders' equity


      $

      2,111,634



      $

      2,108,796


      The following table sets forth our statements of cash flows for the periods indicated (unaudited):

      (in thousands)


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Operating Activities





      Net income (loss)


      $

      (46,443)



      $

      (23,804)


      Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:





      Share-based compensation


      12,711



      1,077


      Depreciation and amortization


      4,076



      1,636


      Amortization of intangible assets


      47,029



      47,029


      Amortization of debt discount and issuance costs


      1,262



      1,058


      Change in fair value of contingent consideration


      —



      19,700


      Loss on extinguishment of debt


      11,935



      —


      Other non-cash items


      (884)



      (458)


      Changes in assets and liabilities, net of acquisition:





      Accounts receivable


      (2,702)



      12,383


      Commissions receivable


      (63,675)



      (58,709)


      Prepaid expenses and other assets


      (11,778)



      1,794


      Accounts payable


      6,114



      (3,467)


      Accrued liabilities


      3,993



      (7,641)


      Deferred revenue


      (36)



      (14,171)


      Commissions payable


      4,742



      18,135


      Other liabilities


      1,406



      1,269


      Net cash provided by (used in) operating activities


      (32,250)



      (4,169)


      Investing Activities





      Purchases of property, equipment and software


      (7,909)



      (7,764)


      Net cash provided by (used in) investing activities


      (7,909)



      (7,764)


      Financing Activities





      Proceeds received upon issuance of common units


      —



      10,000


      Borrowings under term loans


      310,000



      117,000


      Payments of term loans


      (296,835)



      (1,793)


      Call premium paid for debt extinguishment


      (5,910)



      —


      Payment of deferred offering costs


      —



      (874)


      Debt issuance cost payments


      (1,608)



      (6,289)


      Principal payments under capital lease obligations


      (154)



      (144)


      Cash received on advancement to NVX Holdings, Inc.


      3,395



      —


      Net cash provided by (used in) financing activities


      8,888



      117,900


      Effect of exchange rate changes on cash and cash equivalents


      (100)



      98


      Increase in cash and cash equivalents


      (31,371)



      106,065


      Cash and cash equivalents at beginning of period


      144,234



      12,276


      Cash and cash equivalents at end of period


      $

      112,863



      $

      118,341


      Supplemental Disclosure of Cash Flow Information





      Non-cash investing and financing activities:





      Purchases of property, equipment and software included in accounts payable


      $

      2,233



      $

      798


      Issuance of senior preferred earnout units to settle contingent consideration liability


      $

      —



      $

      100,000


      Issuance of common A and B units to settle contingent consideration liability


      $

      —



      $

      100,000


      The following tables set forth operating segment results for the periods indicated (unaudited):

      (in thousands, except percentages)


      Three months ended Jun.
      30, 2021


      Three months ended Jun.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Medicare - Internal


      $

      160,433



      81.5

      %


      $

      87,201



      68.7

      %


      $

      73,232



      84.0

      %

      Medicare - External


      31,379



      15.9

      %


      28,108



      22.1

      %


      3,271



      11.6

      %

      IFP and Other - Internal


      3,788



      1.9

      %


      7,019



      5.5

      %


      (3,231)



      (46.0)

      %

      IFP and Other - External


      1,302



      0.7

      %


      4,729



      3.7

      %


      (3,427)



      (72.5)

      %

      Net revenues


      196,902



      100.0

      %


      127,057



      100.0

      %


      69,845



      55.0

      %

      Segment profit (loss):













      Medicare - Internal


      31,257



      15.9

      %


      32,746



      25.8

      %


      (1,489)



      (4.5)

      %

      Medicare - External


      (1,688)



      (0.9)

      %


      495



      0.4

      %


      (2,183)



      N/M

      IFP and Other - Internal


      (800)



      (0.4)

      %


      (54)



      —

      %


      (746)



      N/M

      IFP and Other - External


      (57)



      —

      %


      130



      0.1

      %


      (187)



      (143.8)

      %

      Segment profit


      28,712



      14.6

      %


      33,317



      26.2

      %


      (4,605)



      (13.8)

      %

      Corporate expense


      24,148



      12.3

      %


      8,911



      7.0

      %


      15,237



      171.0

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      15,300



      12.0

      %


      (15,300)



      N/M

      Amortization of intangible assets


      23,515



      11.9

      %


      23,514



      18.5

      %


      1



      —

      %

      Loss on extinguishment of debt


      11,935



      6.1

      %


      —



      —

      %


      11,935



      N/M

      Interest expense


      8,277



      4.2

      %


      8,986



      7.1

      %


      (709)



      (7.9)

      %

      Other (income) expense


      44



      —

      %


      (505)



      (0.4)

      %


      549



      N/M

      Income (loss) before income taxes


      $

      (39,207)



      (19.9)

      %


      $

      (22,889)



      (18.0)

      %


      $

      (16,318)



      71.3

      %

      _________________________

      NM = Not meaningful




      Six months ended Jun. 30,
      2021


      Six months ended Jun.
      30, 2020





      (in thousands, except percentages)


      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Medicare - Internal


      $

      317,786



      79.2

      %


      $

      182,488



      68.1

      %


      $

      135,298



      74.1

      %

      Medicare - External


      70,879



      17.7

      %


      57,053



      21.3

      %


      13,826



      24.2

      %

      IFP and Other - Internal


      7,763



      1.9

      %


      15,651



      5.8

      %


      (7,888)



      (50.4)

      %

      IFP and Other - External


      4,653



      1.2

      %


      12,875



      4.8

      %


      (8,222)



      (63.9)

      %

      Net revenues


      401,081



      100.0

      %


      268,067



      100.0

      %


      133,014



      49.6

      %

      Segment profit:













      Medicare - Internal


      77,700



      19.4

      %


      74,482



      27.8

      %


      3,218



      4.3

      %

      Medicare - External


      (2,319)



      (0.6)

      %


      173



      0.1

      %


      (2,492)



      N/M

      IFP and Other - Internal


      (1,529)



      (0.4)

      %


      427



      0.2

      %


      (1,956)



      N/M

      IFP and Other - External


      103



      —

      %


      642



      0.2

      %


      (539)



      (84.0)

      %

      Segment profit


      73,955



      18.4

      %


      75,724



      28.2

      %


      (1,769)



      (2.3)

      %

      Corporate expense


      44,475



      11.1

      %


      17,576



      6.6

      %


      26,899



      153.0

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      19,700



      7.3

      %


      (19,700)



      N/M

      Amortization of intangible assets


      47,029



      11.7

      %


      47,029



      17.5

      %


      —



      —

      %

      Loss on extinguishment of debt


      11,935



      3.0

      %


      —



      —

      %


      11,935



      N/M

      Interest expense


      16,965



      4.2

      %


      15,742



      5.9

      %


      1,223



      7.8

      %

      Other (income) expense


      57



      —

      %


      (495)



      (0.2)

      %


      552



      N/M

      Income (loss) before income taxes


      $

      (46,506)



      (11.6)

      %


      $

      (23,828)



      (8.9)

      %


      $

      (22,678)



      95.2

      %

      _________________________

      NM = Not meaningful


      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020, for those submissions that are commissionable (compensated through commissions received from carriers):

      Medicare - Total Commissionable Submitted Policies


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun. 30,
      2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Medicare Advantage


      153,163


      99,078


      326,037


      216,413

      Medicare Supplement


      1,022


      2,248


      2,126


      4,919

      Prescription Drug Plans


      2,374


      1,969


      4,967


      4,431

      Total Medicare


      156,559


      103,295


      333,130


      225,763

      The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for three and six months ended June 30, 2021 and 2020. Only commissionable policies are used to calculate LTV.

      Medicare - Internal Commissionable Approved Submissions


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun.
      30, 2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Medicare Advantage


      121,299


      67,818


      250,185


      151,426

      Medicare Supplement


      268


      465


      519


      1,287

      Prescription Drug Plans


      2,033


      1,571


      4,317


      3,745

      Total Medicare


      123,600


      69,854


      255,021


      156,458

      Medicare - External Commissionable Approved Submissions


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun.
      30, 2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Medicare Advantage


      31,450


      28,979


      73,691


      61,266

      Medicare Supplement


      665


      1,633


      1,396


      3,191

      Prescription Drug Plans


      236


      405


      525


      854

      Total Medicare


      32,351


      31,017


      75,612


      65,311

      The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020:

      LTV per Approved Submission


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun.
      30, 2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Medicare Advantage


      $

      953


      $

      905


      $

      975


      $

      877

      Medicare Supplement


      $

      846


      $

      937


      $

      821


      $

      928

      Prescription Drug Plans


      $

      215


      $

      215


      $

      215


      $

      216

      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:

      Medicare - Total Non-Commissionable Submitted Policies


      Three
      months
      ended Jun.
      30, 2021


      Three
      months
      ended Jun.
      30, 2020


      Six months
      ended Jun.
      30, 2021


      Six months
      ended Jun.
      30, 2020

      Medicare Advantage


      3,232


      7,407


      9,171


      14,334

      Medicare Supplement


      2,042


      1,734


      3,692


      3,546

      Prescription Drug Plans


      791


      955


      1,676


      1,753

      Total Medicare


      6,065


      10,096


      14,539


      19,633

      The following table presents a reconciliation from net income to non-GAAP Adjusted EBITDA guidance for the twelve months ended December 31, 2021:



      Twelve months ended

      Dec. 31, 2021



      Guidance Range

      (in thousands)


      Low


      High

      Net revenues


      $

      1,200,000



      $

      1,300,000


      Net income


      127,665



      157,665


      Interest expense


      30,000



      30,000


      Income tax expense


      220



      220


      Depreciation and amortization expense


      102,000



      102,000


      EBITDA


      259,885



      289,885


      Loss on extinguishment of debt (1)


      11,935



      11,935


      Share-based compensation expense (2)


      28,000



      28,000


      Legal fees (3)


      180



      180


      Adjusted EBITDA


      $

      300,000



      $

      330,000


      Adjusted EBITDA margin


      25

      %


      25

      %

      _________________________

      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (3)

      Represents non-recurring legal fees unrelated to our core operations.

      SOURCE GoHealth, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.